An interventional study of MyMammogram and Provider communication in Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center. Recruiting at 3 sites in United States. Open to female participants aged 39 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Dartmouth-Hitchcock Medical Center · Not applicable, Interventional, and Prevention
Among 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center — 6 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Dartmouth-Hitchcock Medical Center.
Among the 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center, this one is the 13th largest by planned enrollment of the 34 interventional ones, is one of 3 that started in 2025, is one of 19 with no phase, and was the 40th registered.
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's planned enrollment of 39 is below the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →6 of the 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center are open now, in 1 country. Each count lists the studies.
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 39 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →44 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2025.
Median enrollment 30 across the 34 interventional studies, 19 across the 10 observational. Of the 35 that completed or were terminated, 10 (29%) have results posted.
Dartmouth-Hitchcock Medical Center is the lead sponsor of 488 studies on the registry; 71 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 21 (68%) have results posted.
3 of the studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06522568Dartmouth-Hitchcock Medical CenterTesting a Mammography Decision Intervention in a Rural Setting | 2027-01-20 |
| NCT07706556Dartmouth-Hitchcock Medical CenterPilot SMART of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors | 2027-04-03 |
| NCT05716516Dartmouth-Hitchcock Medical CenterSTUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER) | 2027-05 |
Among the 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center, from their registry updates:
The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. In consultation with patients, PCPs, and informatics experts, the study team will refine site selection, randomization, patient and PCP recruitment, and data collection protocols to meet the needs of the rural health care delivery system and participants. The result of this aim will be a modified protocol and intervention strategy that is acceptable to partners. (2) Adapt and test trial and intervention implementation features to achieve protocol acceptance and adherence. The investigators will pilot the adapted three-arm randomized trial protocol in rural primary care settings that compares the MyMammogram DA with or without a risk summary provided to the PCP pre-visit, relative to usual care. Implementing the trial in two phases (n=15 each) will systematically identify barriers and facilitators to trial participation to refine protocols. Participants will receive acceptability surveys and investigators will conduct qualitative interviews with patients and PCPs to understand experiences with trial implementation from multiple perspectives.
This is a three-arm randomized pilot trial that will enroll 30 participants over two study phases. The main objective is to achieve data on trial feasibility (recruitment, retention, randomization, adherence, and acceptability). The primary outcome is Intervention Acceptability.
Procedures: PCPs will be randomized to one of the three arms to prevent contamination across patients (usual care, decision aid, decision aid + clinician communication). Patients will be considered for enrollment if they are aged 40-49, English or Spanish-speaking, have an upcoming primary care visit within 4 weeks, no history of breast cancer, ductal carcinoma in situ, lobular carcinoma in situ, or atypical hyperplasia, and no mammogram within the past 12 months. These patients will be identified via the electronic health record using routine data reports provided to the study team.
Data Collection: Surveys will be conducted at baseline (pre-intervention), post-DA and Post-Visit. Mammography screening information will be collected via medical records, and implementation data will be completed with patients and clinicians who were exposed to the decision aid intervention.
Analysis: All feasibility metrics will be summarized quantitatively, distributions examined for central tendency and spread, and all data assessed for completeness. Data will be presented in a tabular format, with means and standard deviations summarized for the Acceptability of Intervention Measure. Process data will likewise be summarized, reporting proportions of participants meeting each metric (recruitment, retention, randomization, adherence).
Patient Inclusion Criteria:
Patient Exclusion Criteria:
Clinician inclusion: Any practicing primary care provider at a participating site.
Usual care.
Patient uses MyMammogram prior to appointment.
Behavioral: MyMammogram
Patient uses MyMammogram prior to appointment. Provider receives a summary from MyMammogram prior to appointment.
Behavioral: MyMammogram · Other: Provider communication
An online breast cancer screening decision aid
Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment
Intervention acceptability
The acceptability e-scale is a 6-item measure for electronically-delivered interventions, where higher scores indicate greater acceptability. Scores range from 6-30.
Time frame: within one day of completing the intervention
Recruitment feasibility
Measured as the proportion of eligible participants who receive an initial outreach letter and complete the consent process and enroll prior to their clinical visit.
Time frame: 4 weeks
Retention feasibility
Proportion of participants enrolled who complete all study survey time points, reported per trial arm
Time frame: 8 weeks
Knowledge
10-item measure of breast cancer and screening knowledge that is summed for a score from 0-10 (0 indicates lower knowledge, 10 indicates higher knowledge).
Time frame: enrollment and within one day of completing the intervention
Decisional Quality
Decisional Quality is measured using the Decisional Conflict Scale for Low Literacy, a 10-item measure. Scores Range 0-100. Lower scores indicate better decisional quality (lower conflict).
Time frame: enrollment, within one day of completing the intervention, within one day of completing a clinical visit
Screening Intentions
Screening intentions are using two methods. 1) As the likelihood of obtaining a mammogram in the next year (5-point Likert scale); and 2) Using 2 items to measure age at which someone intends to begin screening (40, 45, 50, other) and interval (annual, biennial, other).
Time frame: enrollment, within one day of completing the intervention, within one day of completing a clinical visit
Shared Decision-Making
Shared Decision Making will be assessed with the 3-item, validated CollaboRATE measure. Scored 0-100 (higher scores indicate more shared decision-making).
Time frame: within one day of completing a clinical visit
Self-efficacy
Measured using a validated scale measuring perceived confidence one's personal ability to obtain a mammogram. Ten items are summed, with a theoretical score range from 5-10 (higher scores indicate better self-efficacy).
Time frame: enrollment and within one day of completing a clinical visit
Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.
Of 2,661 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 16 months is below that.
Counting every sponsor, half of 2,771 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dartmouth-Hitchcock Medical Center →